Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05774184 · ClinicalTrials.gov registry record · Phase 2
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
A Phase 2 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT05774184 is a Phase 2 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 86 participants.
The verdict
NCT05774184, a Phase 2 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.
Interventions
- DRUG Matching Placebo
- BIOLOGICAL barzolvolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2026-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05774184
The ClinicalTrials.gov registry entry for NCT05774184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT05774184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05774184 about?
NCT05774184 is a clinical study titled "A Study of CDX-0159 in Patients With Eosinophilic Esophagitis". The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.
What is the current status of trial NCT05774184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2023-06-01. Estimated completion is 2026-01-23.
What interventions are being tested in trial NCT05774184?
The interventions under investigation include: Matching Placebo (DRUG), barzolvolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05774184?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.